Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track AVTX with free AI briefings, catalyst countdowns, and dilution alerts.

AVTX · Avalo Therapeutics, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$393M Cash on Hand
74.8mo Cash Runway
Follow AVTX by email Get an email when AVTX reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about AVTX, unsubscribe in one click. Privacy

📣 What AVTX Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
AVTX-002 Non-Eosinophilic Asthma Phase 2 · NCT05288504 Completed
AVTX-009 Regimen 1 Hidradenitis Suppurativa Phase 2 · NCT06603077 Completed
AVTX-009 Regimen 2 Hidradenitis Suppurativa Phase 2 · NCT06603077 Completed
CERC-301 Major Depressive Disorder Phase 2 · NCT01941043 Completed
FP01 Chronic Refractory Cough Phase 2 · NCT01703923 Completed
Camoteskimab (AEVI-007) Multiple Myeloma Phase 1 · NCT04671251 Completed
mTOR Kinase Inhibitor CERC-006 Lymphatic Malformation Phase 1 · NCT04994002 Withdrawn
MDGN-002 Crohn Disease Phase 1 · NCT03169894 Terminated

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

AVTX holds $393M in cash and short-term investments (as of Sep 30, 2026) and burns about $15.8M/quarter from operations, an estimated runway of 74.8 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 30 · Moderate

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when AVTX files for a raise →

👥 Who Owns AVTX

Insiders 0.6% Other 5%+ holders 5.2% Institutions (198 holders) 94.2% Public and other holders 0%
HolderTypeShares% of sharesAs of
Commodore Capital LP Institution (13G, 5%+) 5,721,109 9.89% 2026-06-11
Farallon Capital Management, L.L.C. Institution (13G, 5%+) 3,974,000 6.87% 2026-09-30
Deep Track Capital, LP Institution (13G, 5%+) 3,610,000 6.24% 2026-06-30
RA Capital Management, L.P. Institution (13G, 5%+) 3,483,099 6.02% 2026-06-30
BlackRock, Inc. Institution (13G, 5%+) 3,415,731 5.91% 2026-06-30
Caligan Partners LP Institution (13G, 5%+) 3,163,866 5.47% 2026-06-30
TCG Crossover GP II, LLC 5%+ holder (13G) 3,017,120 5.22% 2026-05-05
Affinity Asset Advisors, LLC Institution (13G, 5%+) 2,900,000 5.02% 2026-06-30
Trails Edge Capital Partners, LP Institution (13G, 5%+) 2,803,761 4.85% 2026-10-22
Garry Arthur Neil
Chief Executive Officer, Director
Insider 190,314 0.33% 2026-05-21
Mittie Doyle
Chief Medical Officer · +237,484 options
Insider 51,776 0.09% 2026-08-28
Christopher Ryan Sullivan
Chief Financial Officer · +189,663 options
Insider 39,900 0.07% 2026-09-16

Share count 57,823,083 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full AVTX picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for AVTX and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.